Efficacy and Safety of Empagliflozin Monotherapy for 52 Weeks in Japanese Patients with Type 2 Diabetes: A Randomized, Double-Blind, Parallel-Group Study
Crossref DOI link: https://doi.org/10.1007/s12325-015-0198-0
Published Online: 2015-04-07
Published Print: 2015-04
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Kadowaki, Takashi
Haneda, Masakazu
Inagaki, Nobuya
Terauchi, Yasuo
Taniguchi, Atsushi
Koiwai, Kazuki
Rattunde, Henning
Woerle, Hans J.
Broedl, Uli C.
Text and Data Mining valid from 2015-04-01